TCblR Novel Target for Monoclonal Antibody Cancer Therapy
TORONTO, November 21 /CNW/ - Kyto Biopharma Inc. (OTCBB:KBPH), ("Kyto"),
a biotechnology company focused on developing monoclonal antibody based
therapeutic agents for cancer treatment, announced today that for the first
time it has conclusively isolated the protein and gene encoding the human
Vitamin B12 receptor - TCblR for the cellular uptake of the
transcobalamin-bound Vitamin B12. The over expression of TCblR in cancer cells
provides the rationale for targeting the Vitamin B12 receptor in the treatment
of various forms of cancer.
"The discovery of the TCblR gene and the expression of its encoded
receptor protein represents a seminal milestone in the annals of cellular
biology," commented Dr. Uri Sagman, a founder and a director of Kyto.
"Targeting TCblR in cancer cells with monoclonal antibodies holds a tremendous
promise as a strategy to combat cancer," added Dr. Sagman.
The isolation of the TCblR gene and the expression of the TCblR protein
was achieved by Dr. Edward Quadros and his team at the State University of New
York (SUNY) at Downstate Medical Center. In addition, the team at SUNY has
successfully expressed the fragment of the receptor protein responsible for
binding to the transcobalamin - B12 complex. Kyto has embarked on a program to
develop targeted human monoclonal antibodies to TCblR as therapeutics for
various forms of cancer. In addition, Kyto intends to couple chemotherapeutic
drugs and metabolic toxins to such therapeutic monoclonal antibodies and
enhance their biological activity as powerful targeting agents.
Kyto has entered into an arrangement with third party providers to
manufacture murine antibodies that will be used in the development of
humanized monoclonal antibodies to TCblR. Dr. Quadros, with the input of Dr.
Michael Rosenblum of MD Anderson Cancer Center, and a director of Kyto, will
oversee the development of the monoclonal antibody program on behalf of the
ABOUT KYTO BIOPHARMA INC.
Kyto Biopharma Inc. is a Florida incorporated and a Toronto based
biotechnology company that develops monoclonal antibody therapies for the
treatment of various forms of cancer. The Company intends to develop its
Vitamin B12 receptor based technology and is looking for a suitable partner to
assist with the development and commercialization of a marketable cancer
therapeutic. Vitamin B12 regulates one of two major cellular pathways for the
production of Folates, the cell's primary source of carbon and the progenitor
for the synthesis of DNA. The newly isolated vitamin B12 receptor is over
expressed in a host of various forms of cancer cells and serves as a viable
target for development of therapeutic monoclonal antibodies. Kyto holds an
extensive portfolio of intellectual property including IP protection for the
newly discovered TCblR gene and its product.
This release contains forward looking statements that reflect, among
other things, management's current expectations, plans and strategies, all of
which are subject to known and unknown risks, uncertainties and factors that
may cause our actual results to differ materially from those expressed or
implied by these forward-looking statements. Many of these risks are beyond
our ability to control or predict. Please see "Risk Factors" in the Company's
public filings with the Securities and Exchange Commission for a discussion of
such risks, including the Company's need for additional funds, the Company's
dependence on a limited number of therapeutic compounds , the stage of the
products the Company is developing, uncertainties relating to clinical trials
and regulatory reviews, competition and dependence on collaborative partners,
the company's ability to avoid infringement of the patent rights of others,
and the company's ability to obtain adequate patent protection and to enforce
these rights. Because of these risks, uncertainties and assumptions, you
should not place undue reliance on these forward-looking statements.
Furthermore, forward-looking statements speak only as of the date they are
released. Kyto Biopharma does not undertake any obligation to update or review
any such forward-looking information, whether as a result of new information,
future events or otherwise.
For further information:
For further information: Kyto Biopharma Inc. For scientific information:
Dr. Uri Sagman, Director, CRO, (01) 416 436 66 40 or For corporate
information: Georges Benarroch, Director, CEO, (01) 416 955 01 59 (33) 06 07
40 87 06